SS Organics Ltd.
Snapshot View

11.61 +0.55 ▲5.0%

26 July 2021, 04:00:00 P.M.
Volume: 100

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.ssorganics.co.in
Financial Indicators
Market Cap 11.84 Cr.
Earnings per share (EPS) 2.87 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 4.04 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share -37.26 Trailing Twelve Months Ending 2021-03
Price to Book Value -0.31 Calculated using Price: 11.61
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.02 Cr. 10,201,300 Shares
FaceValue 10
Company Profile

SS Organics was incorporated in 1990, is a pharmaceutical company involved in the manufacture and marketing of bulk drugs and intermediates.

A wide range of new generation quinolones, antiasthmatic, antiulcerant, and anti-inflammatory drugs are manufactured. The product range also includes omeprazole, rabeprazole sodium, lansoprazole, esomeprazole magnesium trihydrate, non-pariel seeds, pantoprazole pellets, diclofenac sodium pellets, gabapentior, mooxafloxacin, ramipril, atorvastatin, and voriconazole.

Designed and built as per US FDA standards for production of bulk drugs and custom synthesis of intermediates, the plant located in the Medak district of Andhra Pradesh has an installed capacity 320 TPA. Major export destinations include Europe, USA, South America, and Asia Pacific Region. It reaches the America markets through its subsidiary based in Maryland, USA.

The registered office is at Survey No 252/1, Aroor Village, Sadasivapet Mandal, Medak, Andhra Pradesh.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.97%
1 Week
+21.32%
1 Month
+59.04%
3 Month
+59.04%
6 Month
+59.04%
1 Year
+59.04%
2 Year
+59.04%
5 Year
+6.22%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%)
Return on Capital Employed (%) -22.65 -80.52 -183.16
Return on Assets (%) -1.73 -10.98 -24.53 -33.71 -29.05 -29.92 -25.13 -17.07 -29.10

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -3 -5 -9 -16 -22 -27 -32 -35 -41
Non Curr. Liab. 7 11 15 18 21 31 31 40 44
Curr. Liab. 10 11 12 16 21 16 18 17 16
Minority Int.
Equity & Liab. 14 17 18 18 20 19 17 21 19
Non Curr. Assets 13 15 17 13 14 13 13 12 12
Curr. Assets 1 1 2 5 5 6 4 9 7
Misc. Exp. not W/O
Total Assets 14 17 18 18 20 19 17 21 19

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 2 6 12 8 13 21 14
Other Income 0 0 1 1 0 0
Total Income 3 6 12 9 14 21 14
Total Expenditure 0 -2 -6 -10 -17 -13 -17 -23 -22
PBIDT 0 -2 -3 -4 -4 -4 -3 -2 -8
Interest 0 0 -1 -1 -1 -1 -1
Depreciation -1 -3 -1 -1 -1 -1 -1
Taxation 0 1 0 0 0 0
Exceptional Items 4
PAT 0 -2 -4 -6 -6 -6 -5 -3 -6

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 0 -1 -3 -4 1 1 1 -8 -7
Cash Fr. Inv. -3 -2 1 -2 -1 0 -1 -1
Cash Fr. Finan. 0 4 4 3 1 0 -1 8 3
Net Change 1 -1 0 0 0 0 0 -4
Cash & Cash Eqvt 1 0 0 0 0 0 0 -4

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 17.17 17.17 17.17 17.17 17.17 17.17 17.17 17.17 17.17
Public 82.83 82.83 82.83 82.83 82.83 82.83 82.83 82.83 82.83
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 20 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
With reference to the cited subject this is to certify that the details of Securities dematerialized/ rematerialized during the quarter ended 30th June 2021 as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 have been furnished to the Stock exchange where the shares of the Company is listed. The letter dated 05th July 2021 received from Venture Capital and Corporate Investments Private Limited (RTA) confirming the same is enclosed for your reference.

Kindly take the same on record and acknowledge the receipt of the same.
Tue, 20 Jul 2021
Shareholding for the Period Ended June 30 2021
SS Organics Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30 2021. For more details kindly Click here
Fri, 09 Jul 2021
Announcement under Regulation 30 (LODR)-Press Release / Media Release
This is to bring to your kind notice that the suspension in trading of Equity shares of S.S. Organics Ltd will be revoked w.e.f. 16th July 2021 vide its Notice No. 20210709-4 of BSE Limited dated 09th July 2021. Also hereby informing you that as per the Notice of BSE Limited the trading in the securities of the Company will be resumed in P group.

As per the Companys corporate announcement dated 30th June 2021 the trading window for dealing in the securities of the Company for all Designated Persons and their immediate relative(s) shall remain closed from Thursday 1st July 2021 till 48 hours after the declaration of Unaudited financial results of the Company for the first quarter ended 30th June 2021.

The date of Board meeting for declaration of the financial results of the Company for the first quarter ending on 30th June 2021 will be intimated in due course.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Increasing Relative Strength - Benchmark index Increasing Relative Strength - Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Increasing Relative Strength - Sectoral Index Increasing Relative Strength - Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%